dc.contributor.author | Berry, Colin | |
dc.contributor.author | Ibáñez, Borja | |
dc.date.accessioned | 2023-04-26T14:16:01Z | |
dc.date.available | 2023-04-26T14:16:01Z | |
dc.date.issued | 2022-01-04 | |
dc.identifier.citation | J Am Coll Cardiol. 2022 Jan 4;79(1):49-51. | es_ES |
dc.identifier.uri | http://hdl.handle.net/20.500.12105/15902 | |
dc.description.sponsorship | Dr Berry has received research funding from the British Heart Foundation grant (RE/18/6134217), Chief Scientist Office, EPSRC (EP/R511705/1, EP/S030875/1), European Union (754946-2), Medical
Research Council (MR/S018905/1), and UKRI (MC/PC/20014); and is
employed by the University of Glasgow, which holds consultancy and
research agreements for his work with Abbott Vascular, AstraZeneca,
Boehringer Ingelheim, Causeway Therapeutics, Coroventis, Genentech, GlaxoSmithKline, HeartFlow, Menarini, Neovasc, Siemens
Healthcare, and Valo Health. Dr Ibanez is supported by the European
Commission (ERC-CoG grant No 819775) and by the Spanish Ministry
of Science and Innovation (MCN; ‘RETOS 2019’ grant No PID2019-
107332RB-I00). The CNIC is supported by the ISCIII, the Ministry of
Science and Innovation, and the Pro CNIC Foundation. CNIC is a
Severo Ochoa Center of Excellence. | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Elsevier | es_ES |
dc.type.hasVersion | VoR | es_ES |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
dc.subject.mesh | Heart Failure | es_ES |
dc.subject.mesh | Myocardial Infarction | es_ES |
dc.subject.mesh | Hemorrhage | es_ES |
dc.subject.mesh | Humans | es_ES |
dc.subject.mesh | Myocardial Reperfusion | es_ES |
dc.title | Intramyocardial Hemorrhage: The Final Frontier for Preventing Heart Failure Post-Myocardial Infarction. | es_ES |
dc.type | journal article | es_ES |
dc.rights.license | Attribution-NonCommercial-NoDerivatives 4.0 Internacional | * |
dc.identifier.pubmedID | 34991788 | es_ES |
dc.format.volume | 79 | es_ES |
dc.format.number | 1 | es_ES |
dc.format.page | 49 | es_ES |
dc.identifier.doi | 10.1016/j.jacc.2021.11.002 | es_ES |
dc.contributor.funder | British Heart Foundation | es_ES |
dc.contributor.funder | Unión Europea | es_ES |
dc.contributor.funder | Abbott | es_ES |
dc.contributor.funder | AstraZeneca | es_ES |
dc.contributor.funder | Boehringer Ingelheim Fonds | es_ES |
dc.contributor.funder | Genetic Engineering Tech (Genentech) | es_ES |
dc.contributor.funder | GlaxoSmithKline | es_ES |
dc.contributor.funder | Grupo Menarini | es_ES |
dc.contributor.funder | Unión Europea. Comisión Europea. European Research Council (ERC) | es_ES |
dc.contributor.funder | Ministerio de Ciencia e Innovación (España) | es_ES |
dc.contributor.funder | Fundación ProCNIC | es_ES |
dc.contributor.funder | Ministerio de Ciencia e Innovación. Centro de Excelencia Severo Ochoa (España) | es_ES |
dc.description.peerreviewed | Sí | es_ES |
dc.identifier.e-issn | 1558-3597 | es_ES |
dc.relation.publisherversion | https://doi.org/10.1016/j.jacc.2021.11.002 | es_ES |
dc.identifier.journal | Journal of the American College of Cardiology | es_ES |
dc.repisalud.orgCNIC | CNIC::Grupos de investigación::Laboratorio Traslacional para la Imagen y Terapia Cardiovascular | es_ES |
dc.repisalud.institucion | CNIC | es_ES |
dc.relation.projectID | info:eu-repo/grantAgreement/ES/PID2019-107332RB-I00 | es_ES |
dc.rights.accessRights | open access | es_ES |
dc.relation.projectFECYT | info:eu-repo/grantAgreement/EC/H2020/754946-2 | es_ES |
dc.relation.projectFECYT | info:eu-repo/grantAgreement/EC/H2020/ERC/CoG/819775 | es_ES |